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Abstract
The related PIK-like kinases Ataxia-Telangiectasia Mutated (ATM) and ATM- and Rad3-related (ATR) play major roles in the
regulation of cellular responses to DNA damage or replication stress. The pro-apoptotic role of ATM and p53 in response to
ionizing radiation (IR) has been widely investigated. Much less is known about the control of apoptosis following DNA
replication stress. Recent work indicates that Chk1, the downstream phosphorylation target of ATR, protects cells from
apoptosis induced by DNA replication inhibitors as well as IR. The aim of the work reported here was to determine the roles
of ATM- and ATR-protein kinase cascades in the control of apoptosis following replication stress and the relationship
between Chk1-suppressed apoptotic pathways responding to replication stress or IR. ATM and ATR/Chk1 signalling
pathways were manipulated using siRNA-mediated depletions or specific inhibitors in two tumour cell lines or fibroblasts
derived from patients with inherited mutations. We show that depletion of ATM or its downstream phosphorylation targets,
NBS1 and BID, has relatively little effect on apoptosis induced by DNA replication inhibitors, while ATR or Chk1 depletion
strongly enhances cell death induced by such agents in all cells tested. Furthermore, early events occurring after the
disruption of DNA replication (accumulation of RPA foci and RPA34 hyperphosphorylation) in ATR- or Chk1-depleted cells
committed to apoptosis are not detected in ATM-depleted cells. Unlike the Chk1-suppressed pathway responding to IR, the
replication stress-triggered apoptotic pathway did not require ATM and is characterized by activation of caspase 3 in both
p53-proficient and -deficient cells. Taken together, our results show that the ATR-Chk1 signalling pathway plays a major role
in the regulation of death in response to DNA replication stress and that the Chk1-suppressed pathway protecting cells
from replication stress is clearly distinguishable from that protecting cells from IR.
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Introduction
Cells respond to DNA damage by triggering cell cycle arrest,
DNA repair, or death. The related PIK-like kinases ATM (Ataxia-
Telangiectasia Mutated) and ATR (ATM- and Rad3-related) are
major coordinators of this damage response [1]. ATM is central to
the DNA double-strand break (DSB) response. It delays DNA
synthesis and the onset of mitosis following DSB induction by
agents such as ionizing radiation (IR) through a complex signalling
cascade that includes p53, Chk2 and NBS1 as phosphorylation
targets [2–4]. This signalling cascade also plays a major role in the
onset of apoptosis following IR through the p53-mediated
transcriptional activation of pro-apoptotic proteins such as BAX
and PUMA [5–7]. However cells deficient in ATM are only
partially defective in the induction of apoptosis by IR while p53
deficient cells show a more complete resistance [8,9]. These
observations indicate that both ATM-dependent and independent
pathways regulate the induction of apoptosis by IR. Chk2 may be
particularly important for the ATM-independent pathway as
mouse cells with knockouts of both Chk2 and ATM show levels of
apoptosis similar to those found in p532/2 cells [9].
ATR and its downstream phosphorylation target, Chk1, are
generally activated in response to UV and agents that stall DNA
replication forks [10,11]. Activated Chk1 coordinates many of the
cellular responses to replication fork stress. More specifically, it
prevents the inappropriate firing of late replication origins, the
abandonment of replication forks, and premature chromosome
condensation following disruption of replication [12–15]. In
contrast to the proapoptotic role of the ATM-mediated protein
kinase cascade in the response to IR, Chk1 has an anti-apoptotic
effect in the cellular response to replication inhibitors [13,16–18]
as well as IR [19]. SiRNA mediated ablation of Chk1 (but not
Chk2) causes cells arrested in S-phase by a range of replication
inhibitors to undergo apoptosis. This death response is p53
independent, but cells that lack both Chk1 and p21 show a more
robust death response and reduced cell survival [17]. Thus the
Chk1 pathway plays a key role in protecting S-phase cells from
apoptosis during replication stress and p21 mediates this role,
presumably by preventing entry into S-phase. Intriguingly
depletion of the replication helicase cofactor Cdc45 that plays
an essential role in DNA replication origin firing and fork
elongation protects cells lacking Chk1 from undergoing apoptosis,
suggesting that the role of Chk1 in controlling origin firing and
maintaining fork integrity is key to its anti-apoptotic effect [20].
A role for Chk1 in the suppression of apoptosis in response to IR
was revealed in a zebrafish embryo-based screen [19]. The novel
death pathway triggered in p53 mutant embryos in the absence of
Chk1 required ATM, ATR and caspase 2 but not other caspases.
It was further shown that this response was not limited to
Zebrafish as IR triggered a caspase-2 dependent apoptotic
PLoS Genetics | www.plosgenetics.org 1 January 2009 | Volume 5 | Issue 1 | e1000324response in cultured p53-deficient human tumour cells treated
with a Chk1 inhibitor. Taken together these reports establish a
major role for Chk1 in the protection of cells from apoptosis in
response to a wide range of DNA damage.
While the role of the ATM signalling cascade in the induction of
apoptosis following IR is well established, relatively little is known
concerning the contribution of this signalling pathway in response
to replication fork stress. DNA replication inhibitors trigger a rapid
ATM autophosphorylation and ATM-dependent phosphoryla-
tions of Chk2, NBS1 and p53 [21]. More recent work has
implicated BID as a downstream ATM phosphorylation target
and a suppressor of apoptosis in response to DNA replication
inhibitors [22]. In the work reported here we compared the effects
of ATM, NBS1 or BID deficiency on apoptosis with those
obtained following siRNA-mediated depletion of ATR or Chk1.
We show that depletion or loss of ATM, NBS1 or BID has little or
no significant effect on the induction of apoptosis in two human
tumour cell lines or immortalized human fibroblasts treated with
DNA replication inhibitors, even though depletion of ATR or
Chk1 in these cells led to high levels of cell death. Furthermore,
unlike the Chk1 suppressed pathway responding to IR identified in
Zebrafish embryos, the pathway regulated by Chk1 in response to
replication inhibitors was triggered in both p53 proficient and
deficient cell lines, did not require ATM or ATR, and was
primarily characterized by caspase-3 activation.
Results
Effects of ATM, ATR, or Chk1 Depletion on the Induction
of Apoptosis Following Replication Stress
To determine the role of ATM or ATR relative to Chk1 in the
regulation of apoptosis in response to DNA replication stress,
HCT116 cells were treated with control, ATM, ATR, or Chk1
siRNAs (Figure 1A) for 24 hours before treatment with thymidine
or HU. After 24 or 48 hour treatment with replication inhibitors,
cells were fixed, stained with PI, and analysed for DNA content by
flow cytometry or assayed for Annexin V binding. Cells treated for
24 hours with thymidine or HU accumulated in S-phase, however
there was no significant increase in the level of cells with a subG1
DNA content in cultures treated with any of the siRNAs.
After a 48 hour exposure to thymidine or HU, cells treated with
the control siRNA continued to accumulate in S as well as G2 but
there was only a small increase in cells with a subG1 DNA content
relative to controls (Figure 1B & C). HCT116 cells depleted of
Chk1 or ATM showed a cell cycle distribution similar to that
found for cultures treated with the control siRNA while there was
a small increase in the fraction of cells showing a subG1 DNA
content in cultures depleted of ATR. When Chk1 or ATR
depleted cells were treated with thymidine or HU, fewer S or G2
DNA phase cells were detected relative to the cultures treated with
the control siRNA while a markedly higher fraction of cells (40 to
50%) with a subG1 DNA content was evident (Figure 1B & C).
ATM depleted HCT116 cells showed a somewhat different
response following treatment with thymidine or HU. The fraction
of S phase cells increased in these cultures like cultures treated with
control siRNA (Figure 1B). However after thymidine treatment,
ATM-depleted cells arrested earlier in S-phase while HU treated
cells showed a higher frequency of cells with a late S-phase DNA
content. There was an increase in the level of cells with a subG1
DNA content relative to control cultures after a 48 hour exposure
to the inhibitors. This reached significance for HU treated cells but
not those treated with thymidine. Notably the fraction of subG1
cells was consistently lower in ATM depleted cells relative to Chk1
or ATR depleted cultures (Figure 1B & C). Similarly, there was
little effect on the fraction of cells with a subG1 DNA content in
HCT116 cells treated with the ATM inhibitor KU-55933 [23]
following a 48 hour exposure to thymidine (Figure S1). p53
defective SW480 cells depleted of Chk1 or ATR also had a
significantly higher level of subG1 cells than those depleted of
ATM following a 48 hour treatment with HU (Figure S2).
Analysis of Annexin V+ cells gave similar results (Figure 1D).
HCT116 cultures depleted of either Chk1 or ATR showed a
significant increase in the level of Annexin V+ cells relative to
those treated with the control siRNA following either thymidine or
HU treatment. The fraction of Annexin V+ cells in ATM depleted
cultures exposed to thymidine or HU increased relative to control
siRNA treated cells but this did not reach significance for either
replication inhibitor.
Co-Depletion of ATM or ATR and Chk1 Does Not Further
Enhance or Suppress Apoptosis in Response to
Replication Inhibitors
To determine whether the depletions of these checkpoint
proteins affected apoptosis through related pathways, HCT116
cells were treated with combinations of siRNAs for the checkpoint
proteins (Figure 2A). Apoptotic responses after treatment with
thymidine were measured by the AnnexinV assay. In cultures
depleted of both Chk1 and ATR, the increased level of
AnnexinV+ cells was not significantly different from that produced
by depletion of either protein alone (Figure 2B). When HCT116
cells were depleted of both Chk1 and ATM there was no
significant difference in the fraction of AnnexinV+ cells relative to
cultures depleted of Chk1 alone, although the level of apoptotic
cells was significantly higher than that found in cells depleted of
ATM alone (Figure 2C).
We further examined the induction of apoptosis following
treatment with replication inhibitors in an immortalized human
fibroblast line derived from an AT patient (pEBS) and a derivative
of this line corrected for the ATM defect (YZ5) [24]. In these
cultures, the level of pEBS fibroblasts with a subG1 DNA content
was not significantly different from that found in the ATM
corrected cells following treatment with thymidine (Figure 2D).
However, cultures of both pEBS and YZ5 depleted of Chk1
(Figure 2E) showed a significantly higher level of cells with a
subG1 DNA content relative to controls following thymidine
treatment (Figure 2D). Furthermore there was no significant
Author Summary
The integrity of the genetic information in cells is
protected by elaborate mechanisms that ensure that an
accurate DNA copy is passed from generation to
generation. These mechanisms repair errors in DNA
sequence or stop growth if DNA structure is compromised.
However, if the level of DNA damage is too severe, cells
may also respond by inducing death rather than attempt
repair. Relatively little is known about how cells decide
whether to repair damage or commit to death. The
purpose of our work was to identify genes that control this
decision-making process while cells are duplicating DNA.
We show that two genes play a major role in this process;
however, our work also suggests considerable complexity
in this death response as different death pathways are
triggered in response to different forms of DNA damage.
Since DNA replication inhibitors are used widely in the
treatment of cancer, our work may enable us to more
effectively kill cancer cells in treatment protocols employ-
ing these agents.
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PLoS Genetics | www.plosgenetics.org 2 January 2009 | Volume 5 | Issue 1 | e1000324Figure 1. Effects of ATM, ATR or Chk1 depletion on the induction of apoptosis following replication fork stress. A) Protein levels
48 hours after transfection of the indicated siRNAs in HCT116 cells. b-actin levels are presented as a loading control. B) Representative cell cycle
distributions of HCT116 cultures transfected with indicated siRNAs 24 hours before treatment with 2 mM thymidine or 0.5 mM hydroxyurea for
48 hours. Shaded profiles represent control cultures not treated with replication inhibitors, unshaded profiles represent cultures treated with HUo r
thymidine (TdR). C & D) Cultures of HCT116 cells transfected with the indicated siRNAs were treated 2 mM thymidine or 0.5 mM HU for 48 hours or
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PLoS Genetics | www.plosgenetics.org 3 January 2009 | Volume 5 | Issue 1 | e1000324Figure 2. Effects of co-depletions of ATM, ATR or Chk1 on apoptosis in response to replication inhibitors. A) ATR and Chk1 protein
levels 48 hours after transfection of the indicated combinations of siRNAs in HCT116 cells. b-actin levels are presented as loading controls. B & C)
Level of apoptotic cells in HCT116 cultures (measured by Annexin V binding) after transfection of the indicated siRNAs following a 48 hour treatment
with 2 mM thymidine. D) Induction of apoptosis (measured as the sub-G1 population) in ATM corrected YZ5 or ATM deficient pEBS cells transfected
with control or Chk1 siRNAs and treated or not treated with 2 mM thymidine for 48 hours. E) Western blot analysis of Chk1 protein levels in the ATM-
deficient pEBS or corrected YZ5 cells after 48 hours treatment with the relevant siRNA. b-actin levels are presented as loading controls. Results in B–D
represent the means of two to three independent experiments6standard deviations. Statistical significance versus thymidine or HU treated control
siRNA transfected cells: ns, not significant; *p,.05.
doi:10.1371/journal.pgen.1000324.g002
left untreated as controls. Cells were then harvested and the level of apoptosis was determined by measuring the percentage of cells containing a
subG1 DNA content by flow cytometry (C) or the percentage of the population binding Annexin V but not PI (D). Results in C and D represent the
means of two to three independent experiments6standard deviations. Statistical significance versus thymidine or HU treated control siRNA
transfected cells: ns, not significant; *p,.05; **p,.005; ***p,.005.
doi:10.1371/journal.pgen.1000324.g001
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lines. Thus our results suggest that Chk1 and ATR regulate
apoptosis in response to replication stress through a common
pathway while ATM does not play a significant role in this
response.
Enhanced Levels of RPA Foci in Cells Depleted of Chk1 or
ATR but not Those Depleted of ATM in Response to
Replication Inhibitors
RPA foci appear as an early event in Chk1 depleted cells in
response to replication inhibitors [20]. We next determined
whether cells depleted of ATR or ATM showed induction of such
foci. HCT116 cells were treated with control, Chk1, ATR, or
ATM siRNAs for 24 hours before treatment with thymidine
(Figure 3A). After 24 hours cells were fixed and stained for RPA.
Following depletion of Chk1 or ATR, RPA foci accumulated (.10
foci/cell) in up to 50 to 60% of cells following treatment with
thymidine (Figure 3B & C). In contrast cultures depleted of ATM
or treated with the ATM inhibitor KU-55933 showed a
significantly lower percentage of cells accumulating these foci. In
addition hyperphosphorylation of RPA 34 was evident in Chk1 or
ATR depleted HCT116 cells after thymidine treatment but not
cells depleted of ATM (Figure 3D). Since ATM has been reported
to contribute to the phosphorylation of RPA34 following DNA
damage [25], this decrease in the level of phosphorylation could
simply be due to a decrease in ATM kinase activity. However,
RPA34 hyperphosphorylation was also evident in HCT116 cells
depleted of both Chk1 and ATM (Figure 3E). Furthermore AT5
fibroblasts (derived from AT patients) depleted of Chk1 showed
hyperphosphorylation of RPA34 as early as six hours after
thymidine treatment (Figure 3F) demonstrating that cells are still
capable of RPA34 phosphorylation when ATM function is
compromised. Thus the early events detected in Chk1- or ATR-
depleted cells treated with replication inhibitors are not evident in
ATM depleted cells.
Caspase 3 Is Primarily Activated in Chk1-Depleted Cells
but not Those Depleted of ATM Following Thymidine
Treatment
We previously reported that caspase 3 was activated in
HCT116 cells depleted of Chk1 following treatment with
replication inhibitors [17]. To determine whether caspase 3 was
activated in cells depleted of ATM, HCT116 cells treated with
control, Chk1, ATR or ATM siRNAs were exposed to thymidine
for 24 or 48 hours. Activated caspase 3 was assayed by Western
blotting using cell free lysates prepared from these cultures. This
analysis revealed a strong increase in the level of the activated
(cleaved) form of caspase 3 in Chk1 or ATR depleted HCT116
cells exposed to thymidine (Figure 4A). A lower level of the
activated caspase 3 was detected in HCT116 cells treated with
control or ATM siRNAs following exposure to thymidine
consistent with the lower level of apoptosis found in such cells.
Recently it was reported that p53 deficient cells treated with a
Chk1 inhibitor or siRNA showed cleavage of caspase 2 but not
caspase 3 following exposure to IR while p53+/+ HCT116 cells
predominantly showedcleavage of caspase 3 [19]. To determine the
effect of p53 status on caspase 2 and 3 cleavage in Chk1 depleted
cells treated with thymidine, the cleaved forms of these caspases
were analysed in HCT116 p532/2 cells treated with control or
Chk1 siRNAs. In agreement with the previous report, cleaved
caspase 2 was detected in Chk1 depleted HCT116 p532/2 cells
exposed to 10 Gy IR while cleaved caspase 3 was not evident
(Figure 4A & B). Following a 48 hour exposure of Chk1 depleted
HCT116 p532/2 cells to thymidine, there was little change in the
level of the cleavedcaspase 2 relative to cellstreatedwiththe control
siRNA while more robust levels of cleaved caspase 3 were evident
(Figure 4B). Similarly Chk1 depleted SW480 cells (that are defective
in p53 function) showed a weak increase in the level of cleaved
caspase 2 while caspase 3 cleavage was clearly induced (Figure 4C).
Cleaved caspase 2 was not detected in Chk1 depleted p53+/+
HCT116 cells following thymidine treatment (Figure 4A).
To determine whether the induction of apoptosis was
dependent upon caspase 3 activation following thymidine
exposure, Chk1 depleted HCT116 or SW480 cells exposed to
thymidine were treated with the caspase 3 inhibitor II (Z-DEVD-
FMK). In such cultures the accumulation of cells with a subG1
content (Figure 4D) or Annexin V+ cells (Figure 4E) was markedly
reduced. Taken together these results indicate that a caspase 3
dependent pathway is activated in Chk1 depleted cells exposed to
thymidine. In contrast to the response of such cells to IR, caspase 3
activation is not dependent upon p53 status although a low level of
caspase 2 cleavage can be detected in the p53 deficient cells.
Response of NBS1-Deficient Cells to Replication
Inhibitors
Recent work has shown that mice carrying a carboxyl terminus
deletion of NBS1 are defective in apoptosis in many tissues and in
response to IR [9]. To investigate the contribution of NBS1 to
apoptosis in response to DNA replication stress, we determined the
apoptotic response of HCT116 cultures depleted of NBS1 or
immortalized human fibroblasts obtained from Nijmegen break-
age syndrome patients to DNA replication inhibitors. HCT116
cultures depleted of NBS1 (Figure 5A) and treated with thymidine
showed a slightly reduced level of cells in S- and G2-phases relative
to cultures treated with the control siRNA (Figure S3). The
fraction of apoptotic cells in thymidine treated cultures reach
significance (p=0.049) when measured by the Annexin V assay,
but not in the assay of subG1 cells (Figure 5B). The response of
NBS1 depleted cells in either assay was not as robust as that seen
with Chk1 depleted cells. Co-depletion of NBS1 and Chk1 did not
produce any significant changes in the level of apoptotic cells
relative to cells depleted of Chk1 alone. When HCT116 cells
depleted of NBS1 were treated with HU, the level of S and G2-
phase cells was not greatly affected (Figure S3) and the increase in
Annexin V+ or subG1 cells did not reach significance (Figure 5B).
The level of Annexin V+ cells in HCT116 cultures depleted of
both NBS1 and Chk1 was similar to that of cultures depleted of
Chk1 alone.
NBS12/2 fibroblasts (NBS1-LB1) obtained from Nijmegen
breakage syndrome patients and fibroblasts corrected for the
defect (p95wt, [4] were next examined for their response to
replication inhibitors. Thymidine had no significant effect on the
level of cells with a subG1 DNA content in either mutant or
corrected fibroblast lines treated with the control siRNA while HU
produced a small increase in both cell types (Figure 5C & D). Chk1
depletion of the corrected fibroblasts resulted in a ,two-fold
increase in cells with a subG1 DNA content. Intriguingly there was
a ,five-fold increase in the fraction of subG1 cells in Chk1
depleted NBS12/2 fibroblasts (Figure 5C & D). The level of cells
with a subG1 DNA content was significantly increased in mutant
and corrected fibroblasts treated with Chk1 siRNA relative to cells
treated with the control after exposure to either thymidine or HU.
However there were no significant differences in the response of
the NBS12/2 fibroblasts relative to the corrected cells in these
conditions (Figure 5C & D). Interestingly the replication inhibitors
did not further increase the level of apoptosis in the NBS1 LB1
(2/2) cells depleted of Chk1.
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PLoS Genetics | www.plosgenetics.org 5 January 2009 | Volume 5 | Issue 1 | e1000324Figure 3. Induction of RPA foci and RPA34 hyperphosphorylation in cells depleted of Chk1 or ATR but not ATM deficient cells
following thymidine treatment. A) Levels of Chk1, ATR, or ATM proteins following treatment of HCT116 cells with the indicated siRNAs or 10 mM
of the ATM inhibitor (KU55399). B) Representative images of RPA foci obtained by immunostaining of HCT116 cells treated with control, Chk1, ATR, or
ATM siRNAs or 10 mM of the ATM inhibitor KU55399 after a 24 hour thymidine treatment. C) Percentages of cells treated with the indicated siRNAs or
10 mM of the ATM inhibitor KU55399 presenting low (,10 foci/cell) or high (.10 foci/cell) levels of RPA foci after a 24 hour exposure to thymidine. D)
Western blot analysis of RPA34, Chk1, ATR and ATM in extracts from HCT116 cells transfected with the indicated siRNAs and exposed to 2 mM
thymidine for the indicated times. The band showing slower mobility on panel probed with the RPA34 antibody represents hyperphosphorylated
forms of the protein. E) Hyperphosphorylation of RPA34 in HCT116 cells co-depleted of Chk1 and ATM after exposure to 2 mM thymidine for the
indicated times. F) Hyperphosphorylation of RPA34 in the AT fibroblast line AT5 transfected with control or Chk1 siRNAs following exposure to 2 mM
thymidine for the indicated times. Hyperphosphorylated RPA34 was detected by six hours after thymidine treatment. AT5 cells treated with the
control siRNA do not show the slower mobility band characteristic of RPA34 hyperphosphorylation following a 30 hour thymidine treatment.
doi:10.1371/journal.pgen.1000324.g003
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Following Disruption of DNA Replication
Given the controversy arising over recent reports of an anti-
apoptotic role for BID in response to some forms of DNA damage
[26,27], we determined the effect of BID depletion on the
induction of apoptosis following treatment with thymdine or HU.
Depletion of BID in HCT116 (Figure 6A) had only minor effects
on cell cycle distribution after treatment with thymidine or HU
(Figure 6B), although, like ATM depleted cells, an accumulation of
cells in mid S-phase was detected. Similarly there were only small
changes in the level of cells with a subG1 DNA content or
AnnexinV+ after treatment of BID depleted cells relative to cells
treated with the control siRNA (Figure 6B–D). The strong
induction of subG1 or AnnexinV+ cells in cultures depleted of
Chk1 after thymidine or HU treatment was not altered in cells
depleted of both Chk1 and BID. In addition co-depletion of BID
and ATR or BID and ATM had no further effect on the level of
apoptotic cells relative to cells treated with ATR or ATM siRNAs
alone (Figure S4). Thus BID does not appear to play a major role
in the commitment to apoptosis during replication stress in the
tumour cells tested here.
Discussion
In the work reported here we analysed the roles of key proteins
controlling the cellular response to DNA damage in the control of
apoptosis following DNA replication stress. The role of ATM in
promoting apoptosis in response to ionizing radiation is well
established [8,28]. Our data suggest that it plays little or no role in
tumour cell lines in response to DNA replication fork stress relative
to the ATR-Chk1 pathway. SiRNA mediated depletion of ATM
and downstream ATM phosphorylation targets NBS1 and BID
had little or no significant effect on the level of apoptotic cells in
response to the replication inhibitors in the tumour cell lines
tested. We previously reported that Chk2 depletion did not affect
the level of apoptotic cells induced by replication inhibitors [17].
In addition early events occurring after the disruption of DNA
replication (accumulation of RPA foci and RPA34 hyperpho-
sphorylation) in ATR- or Chk1-depleted cells committed to
apoptosis are not detected in ATM-depleted cells. In immortalized
fibroblast lines derived from patients with inherited defects in
ATM or NBS1, there was no difference in the apoptotic response
of mutant cells to replication inhibitors relative to the corrected
lines while depletion of Chk1 or ATR gave robust apoptotic
responses in all cell types. The only exception to this pattern was
NBS12/2 cells that showed an elevated level of apoptosis
following Chk1 depletion in the absence of the replication
inhibitor. Since thymidine or HU treatment of these cells did
not further increase the level of apoptosis, we speculate that the
synthetic lethality observed in these conditions may be a
consequence of some disruption of replication in these cells.
Depletion of ATR or Chk1 leads to a consistent robust
apoptotic response to replication inhibitors in both tumour and
immortalized fibroblast cell lines. The response of the ATR-Chk1
pathway is largely directed at the stabilization of DNA replication
following stress [29] and it does not appear to be required to
activate downstream proapoptotic proteins. The precise event that
initiates the death response in the absence of this signalling
pathway is not yet clear. Previous work showing that the
replication helicase cofactor Cdc45 is required for the Chk1
suppressed apoptotic response suggests that the role of this
signalling pathway in maintaining replication fork integrity and
preventing firing of new origins following the disruption of DNA
replication is critical [20]. Co-depletion of proteins involved in
ATR and ATM signalling pathways does not enhance or inhibit
the apoptotic response to replication inhibitors indicating that the
ATM signalling pathway is not required for the death response.
Interestingly, ATR- and ATM-mediated signalling cascades
overlap in response to many forms of DNA damage. For example,
both pathways stimulate Cdc25A degradation following activation
by DNA damage through the action of the Chk1 and Chk2
checkpoint kinases [2,30]. Thus activation of either pathway can
produce S-phase arrest that, in turn, should favour the anti-
apoptotic repair of damaged DNA. However, in the absence of
Chk1 or ATR, the ATM-mediated response does not appear to be
sufficient to protect cells from apoptosis.
It has been reported that the pro-apoptotic protein BID
participates in ATM-mediated protein kinase cascade to regulate
entry into S-phase and prevent death in response to DNA
replication inhibitors. BID showed nuclear localization and was
phosphorylated in an ATM-dependent manner following DNA
damage in myeloid progenitor cells derived from wild type mice
[22]. Furthermore, cells from BID2/2 mice showed a strong
apoptotic response following treatment that was not evident in
BID+/+ cells. In another report mouse embryo fibroblasts
obtained from BID2/2 mice showed a delayed entry into S-
phase but not cell death following exposure to DNA damaging
agents [31]. More recently these observations were disputed as
several cell types from BID2/2 mice generated on a different
genetic background failed to show any significant change in S-
phase arrest, survival, or apoptosis relative to BID+/+ cells [32]. In
our knockdowns of BID in the human colon cancer cell line
HCT116, no significant increase in the frequency of apoptotic cells
was observed. However, BID depleted cells treated with thymidine
accumulated in mid S-phase, suggesting that transition through S-
phase was delayed relative to cells treated with the control siRNA.
The data reported here show that the apoptotic pathway
suppressed by Chk1 in response to replication inhibitors is clearly
distinguishable from both the classical intrinsic death pathway and
the Chk1-suppressed IR death response (Figure 7). Unlike the
intrinsic pathway, the Chk1 suppressed response to replication
inhibitors does not require p53 or Chk2. The Chk1 suppressed
Figure 4. Induction of caspase 3 cleavage in HCT116 cells depleted of Chk1 following thymidine treatment. A) Western blot analysis of
caspase 2 (c2) and cleaved caspase 3 (c3) in extracts obtained from HCT116 cells transfected with the indicated siRNAs treated or not treated with
2 mM thymidine for the indicated times. The two lanes furthest to the right present caspase 2 and cleaved caspase 3 levels in HCT116 p532/2 cells
depleted of Chk1 exposed or not exposed to 10 Gy IR. The levels of Chk1, ATR and ATM in the cells treated with the indicated siRNAs are presented.
b-actin levels are presented as loading controls. B) Western blot analysis of caspase 2 and cleaved caspase 3 in extracts obtained from HCT116 p532/2
cells transfected withcontrol orChk1 siRNAs andtreatedor not treatedwith2 mMthymidinefortheindicated times. As above, thetwolanes furthestto
the right present caspase 2 and cleaved caspase 3 levels in HCT116 p532/2 cells depleted of Chk1 exposed or not exposed to 10 Gy IR. The levels of
Chk1 in the cells treated with the indicated siRNAs are presented. C) Western blot analysis of cleaved caspase 2 and cleaved caspase 3 in extracts
obtained from SW480 cells transfected with control, Chk1, or ATM siRNAs and treated or not treated with 2 mM thymidine for the indicated times. D–E)
Cell cycle analysis of HCT116 (D) or SW480 (E) cells transfected with the indicated siRNAs and treated or not treated with 2 mM thymdine for 48 hours.
The indicated cultures were also treated with 100 mM of the caspase 3 inhibitor II, Z-DEVD-FMK. F) HCT116 and SW480 cultures treated as above were
also assayed for AnnexinV+/PI negative cells.
doi:10.1371/journal.pgen.1000324.g004
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PLoS Genetics | www.plosgenetics.org 8 January 2009 | Volume 5 | Issue 1 | e1000324Figure 5. Effect of Nbs1 deficiency on apoptosis in response to replication inhibitors. A) Nbs1 and Chk1 protein levels in HCT116 cells
after 48 hours treatment with the siRNAs for the two proteins. B) Induction of apoptosis measured by Annexin V staining (top panels) or sub-G1
population (bottom panels) in HCT116 cells transfected with control, Nbs1 or Chk1 siRNAs singly or in combination exposed or not exposed to 2 mM
thymidine or 0.5 mM hyroxyurea. C & D) Induction of apoptosis (measured by the percentage of cells with a sub-G1 DNA content) in Nbs1-deficient
(LB1) and corrected (p95wt) fibroblasts transfected with control or Chk1 siRNA following exposure to 2 mM thymidine (C) or 0.5 mM hyroxyurea (D).
Results in B–D represent the means of two to three independent experiments6standard deviations. Statistical significance versus thymidine or HU
treated control siRNA transfected cells: ns, not significant; *p,.05; **p,.005; ***p,.005.
doi:10.1371/journal.pgen.1000324.g005
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depletion of ATR and it requires ATM, ATR and caspase 2
[19]. Although this pathway was identified in screen of p53
deficient zebrafish, p53 deficient human tumour cells treated with
Chk1 inhibitors also show caspase 2 cleavage and caspase 2
dependent apoptosis in response to IR. In p53 proficient tumour
cells, the cleaved caspase 2 is not detected but caspase 3 is
activated under these conditions. In contrast both ATR and Chk1
depleted cells undergo apoptosis in response to replication
inhibitors regardless of p53 status and ATM is not required for
death. Caspase 3 is clearly activated in both p53 proficient and
deficient cell lines. Cleaved caspase 2 is not detected in p53
Figure 6. Effect of BID depletion on the induction of apoptosis following disruption of replication. A) Western blot analysis of Chk1 and
BID in HCT116 cells treated with control, Chk1 and/or BID siRNAs for 48 hours. b-actin levels are presented as loading controls. B) Representative cell
cycle distributions of HCT116 cells transfected with the indicated siRNAs followed by treatment with 2 mM thymidine or 0.5 mM hydroxyurea for
48 hours. Shaded profiles represent control cultures not treated with replication inhibitors, unshaded profiles represent cultures treated with HUo r
thymidine (TdR). C & D) Induction of apoptosis (measured by Annexin V binding) in HCT116 cells following transfection of the indicated siRNAs
exposed or not exposed to 2 mM thymidine (C) or 0.5 mM HU (D) for 48 hours. Results in C & D represent the means of two to three independent
experiments6standard deviations. Statistical significance versus thymidine or HU treated control siRNA transfected cells: ns, not significant; *p,.05;
**p,.005.
doi:10.1371/journal.pgen.1000324.g006
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deficient cells. Thus while Chk1 is required for the suppression of
apoptosis in response to DNA structural alterations induced by IR
or replication stress, the pathways suppressed are distinctly
different.
Given the lethal effects of loss of Chk1 function on tumour cells
exposed to DNA replication inhibitors, there has been interest in
the use of Chk1 inhibitors in chemotherapy. Chk1 is highly
expressed in some types of tumours [33]. This may confer some
growth advantage to tumour cells as a result of the role of this
protein in protecting cells from replication stress that may be
induced by hypoxia or nutrient deprivation during tumour
development [34]. However loss of Chk1 can also be lethal to
some normal cell types [35] and Chk1 knockout mice show
embryonic lethality [36]. Nevertheless recent work has shown that
Chk1 inhibitors can be used to increase the sensitivity of tumour
cells to replication inhibitors in vitro and in vivo [37]. Furthermore,
Chk1 knockdown experiments suggest enhanced lethality for
tumour cells may be obtained where the protein is only partially
depleted, thus reducing potential lethality caused by complete loss
of Chk1. Notably Chk1 inhibitors have been developed that
appear to enhance the toxicity of DNA damaging agents in p53
deficient tumour cells but not p53-proficient cells [38] offering
prospects for the targeted activation of the Chk1-suppressed
apoptotic pathway in at least some types of tumour cells.
Materials and Methods
Cell Lines and Cultures
The HCT116 and SW480 human colon cancer cell lines were
obtained from American Type Culture Collection (Manassas, VA)
while the AT patient derived AT5 cells (TAT5BIVA) was obtained
from the EuropeanCelland Culture Collection. HCT116p532/2
cells were provided by Dr. Bert Vogelstein (Johns Hopkins
University, Baltimore, MD). AT-deficient (AT22IJE-T referred to
as pEBs here) and corrected (YZ5) cell lines were kindly provided by
Dr. Yosef Shiloh (Tel Aviv University, Tel Aviv, Israel). Nbs1
deficient (NBS1-LB1) and corrected (p95wt) fibroblasts were
generously provided by Dr. Mike Kastan (St. Jude Children’s
Research Hospital, Memphis, TN). Cells were maintained in
DMEM supplemented with 10% fetal bovine serum (FBS). For
experiments using thymidine, dialyzed FBS was used to remove
deoxynucleosides in the serum that might interfere in the response
to this agent.
SiRNA Transfection
All siRNAs were obtained from Dharmacon (Lafayette, CO).
The ATM and ATR siRNA consisted of a pool of four sequences
designed to the relevant DNA sequence. Chk1 siRNAs were
designed by J. Blackburn and C. Smythe, (unpublished data). Nbs1
siRNAs (GUCGAUCAGCCGAAAUCAU, CUCACCUUGU-
CAUGGUAUC, and GCUAGGUUGAUAACAGAAG) were
designed by A. Ganesh and the control siRNA was obtained
from Eurogentec (OR-0030-NEG). SiRNA duplexes were trans-
fected into cells using Lipofectamine 2000 (Invitrogen, Paisley,
United Kingdom) according to manufacturer’s instructions. The
cells were then incubated for twenty-four hours before further
treatment.
Cell Cycle Analysis
After treatment, floating (obtained from the medium and a PBS
wash)andadherent(obtainedaftertrypsinization)cellswerepelleted
together by centrifugation. Cell pellets were washed with PBS, fixed
in 70% ice-cold ethanol, and stored at 220uC for up 2 weeks. Cells
were incubated overnight with Propidium Iodide as described
previously [17]. Stained nuclei were analyzed on a FACScan (BD
Biosciences, Franklin Lakes, NJ) using CellQuest software.
Detection of Apoptosis
Apoptotic cells were examined using fluorescein isothiocyanate
(FITC)-Annexin V and PI detection kit according to the
manufacturer’s instructions (BD Biosciences). The cells were
analyzed by flow cytometry and the percentage of early apoptotic
(% Annexin V/PI) cells is presented.
Immunofluorescence Analysis
Cells were grown on glass coverslips, treated as indicated, fixed
with 3% buffered paraformaldehyde for 15 minutes at room
temperature (RT) and permeabilized in PBS containing 0.5%
Triton X-100 for 8 minutes at RT. Cells were then incubated with
1/250 diluted anti-RPA34 (NA19L; Calbiochem) for 45 minutes
at RT and 1:500 diluted Alexa-594 conjugated anti-mouse IgG
(A11005; Molecular Probes, Invitrogen) for 30 minutes at RT and
in the dark. Antibody dilutions and washes after incubations were
performed in PBS containing 0.5%BSA and 0.05%Tween 20.
Coverslips were finally mounted in Vectashield mounting medium
with DAPI (H-1500; Vector Laboratories Inc.). For fluorescent
analysis, a Nikon Eclipse T200 microscope equipped with a
Hamamatsu Orca ER camera and the Volocity 3.6.1 (Improvi-
sion) software was used.
Western Blotting
Cell extracts were prepared and fractionated on SDS-PAGE
gels before being blotted onto nitrocellulose (Whatman Schleicher
and Schuell, Dassel, Germany) as described previously [21].
Proteins were detected with the ECL detection system (GE
Healthcare, Little Chalfont, Buckinghamshire, United Kingdom)
using antibodies recognizing ATM (GeneTex Inc, San Antonio,
Texas), ATR, (Santa Cruz Biotechnology, Santa Cruz, CA), BID
Figure 7. Model of apoptotic pathways suppressed by Chk1
following IR or DNA replication stress. Replication stress
developing as a result of DSB formation or processing triggers the
ATR/Chk1 protein kinase cascade that suppresses an ATM- and ATR-
dependent cleavage of caspase 2 and cell death (left, from [19]).
Replication stress triggered by DNA replication inhibitors also triggers
the ATR/Chk1 protein kinase cascade that suppresses an apoptotic
pathway (right). In Chk1 depleted cells treated with replication
inhibitors RPA foci accumulate, caspase 3 is activated, and apoptosis
follows. Once this apoptotic response is triggered in the absence of
Chk1 or ATR, it does not require ATM or ATR function, unlike the
response to IR. The formation of RPA foci and apoptosis are dependent
upon Cdc45 function and are modulated by p21 [17,20].
doi:10.1371/journal.pgen.1000324.g007
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Beverly, MA), NBS1 (Cell Signaling Technology), and b-actin
(Sigma-Aldrich), RPA34 (NA19L; Calbiochem), Caspase-2
(MAB3507; Millipore), cleaved caspase-3 (ab32042; Abcam).
Supporting Information
Figure S1 Induction of apoptosis is only weakly increased in
HCT116 cells treated with the ATM inhibitor KU-55933
following thymidine treatment. HCT116 cells were treated with
control or Chk1 siRNAs and/or 10 mM of the ATM inhibitor
KU-55933 before a 48 hour treatment with 2 mM thymidine.
Cells were then harvested and the cell cycle distribution of PI
stained cells was analysed by flow cytometry. Cells with a subG1
DNA content were scored as apoptotic. Shaded profiles represent
control cultures not treated with replication inhibitors, unshaded
profiles represent cultures treated with thymidine (TdR).
Found at: doi:10.1371/journal.pgen.1000324.s001 (0.92 MB TIF)
Figure S2 Effects of ATM, ATR or Chk1 depletion on the
induction of apoptosis following replication fork stress in SW480
cells. Induction of apoptosis in ATM-, ATR, or Chk1-depleted
SW480 cells measured by the percentage of population having a
sub-G1 DNA content following 48 hour treatment with 0.5 mM
HU. Results represent the means of two to three independent
experiments6standard deviations. Statistical significance versus
HU treated control siRNA transfected cells: ns, not significant;
*p,.05.
Found at: doi:10.1371/journal.pgen.1000324.s002 (0.42 MB TIF)
Figure S3 Cell cycle analysis of HCT116 cells treated with Chk1
and NBS1 siRNAs singly or in combination in the presence or
absence of thymidine. HCT116 cells were transfected with the
indicated siRNAs and after 48 hours were treated with 2 mM
thymidine or 0.5 mM HU for 48 hours. Cells were then PI stained
and analysed for DNA content by flow cytometry. Shaded profiles
represent control cultures not treated with replication inhibitors,
unshaded profiles represent cultures treated with HU or thymidine
(TdR).
Found at: doi:10.1371/journal.pgen.1000324.s003 (0.88 MB TIF)
Figure S4 BID depletion has no significant effect on the
induction of apoptosis following disruption of DNA replication.
Induction of apoptosis in HCT116 cells transfected with the
indicated siRNAs (A) singly or in combination and treated or not
treated with 2 mM thymidine or 0.5 mM hydroxyurea. Apoptosis
was measured by the percentage of cells with a subG1 DNA
content (B) or those that were Annexin V+/PI negative (C & D).
Results represent the means of two to three independent
experiments6standard deviations. Statistical significance versus
HU treated control siRNA transfected cells: ns, not significant;
*p,.05; **p,.005.
Found at: doi:10.1371/journal.pgen.1000324.s004 (0.81 MB TIF)
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